Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
version: 26; Last updated: 2025-08-18 13:22:42+0000
Profile: ComparativeEvidence
ArtifactPublicationStatus: Active
url: https://fevir.net/resources/Evidence/367949
identifier: FEvIR Object Identifier/367949, FEvIR Linking Identifier/NCT03640312-secondaryOutcomeMeasure-7-OutcomeAnalysis-8-BetweenGroupAnalysis-OG000-OG001
name: NCT03640312_secondaryOutcomeMeasure_7_OutcomeAnalysis_8_BetweenGroupAnalysis_OG000_OG001
title: Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
citeAs:
Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367949. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367949. Computable resource at: https://fevir.net/resources/Evidence/367949#json.
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
publisher: Computable Publishing LLC
contact: support@computablepublishing.com
copyright:
https://creativecommons.org/licenses/by-nc-sa/4.0/
description:
Statistical test for difference in Physical Health T Score
variableDefinition
note:
Data are available on only 28 participants in the intervention group for the mental health T score.
variableRole: Population
intended: Group NCT03640312 Eligibility Criteria
variableDefinition
description:
Group Assignment: QUARTET LDQT vs. Candesartan
variableRole: Exposure
comparatorCategory: Candesartan
observed: Group Assignment: Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States. QUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks. vs. Patients randomized to the comparison arm took a once daily 8mg candesartan. Candesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.
variableDefinition
variableRole: Outcome
observed: Health-related Quality of Life at 12 weeks (NCT03640312)
statistic
note:
Outcome Analysis NonInferiority Type: Superiority
statisticType: Mean Difference (Net)
quantity: -3.45 score on a scale
attributeEstimate
type: standard error of the mean
quantity: 2.01 score on a scale
attributeEstimate
note:
Adjusted for baseline T score
type: P-value
quantity: 0.09
attributeEstimate
note:
CI Number of Sides: 2-Sided
type: Confidence interval
level: 0.95
range: -7.49-0.59 score on a scale
ModelCharacteristics
Code ANCOVA